Adamant Biomedical Investments

Adamant Biomedical Investments AG was a specialized Swiss asset management firm focused exclusively on the healthcare and life sciences sectors. Established in 2000 as a joint venture between Swiss Life Asset Management and partners from the Bellevue Group, the company managed a variety of investment funds and mandates covering biotechnology, medical technology, and pharmaceuticals. The firm was recognized for its "Diamond" investment strategy, which aimed to balance high-growth biotech investments with more stable medtech and specialty pharma holdings. In 2014, Adamant was acquired by Bellevue Group, and its fund portfolio was fully integrated into Bellevue Asset Management on January 1, 2015.